Recently, the newspaper Folha de São Paulo, from Brazil, published an article detailing how the company Recepta Biopharma plans to launch a type of cancer treatment that costs a fifth of what it is today.
The plan is to create a similar molecule that will replace the one created by the labs, but maintaining the same successful structure of big pharmaceutical companies like Bristo Myers-Squibb (BMS), owner of Opdivo (nivolumabe) and Yervoy (ipilumumae), and of the MSD (Merck, in the United States), owner of Keytruda (pembrolizumabe).
The development of these medications would count on the financing from Finep and of BNDES, today partners of Recepta; the money from research agencies like CNPq and Fapesp; and it would also count with partnerships from universities such as USP and Unifesp and foreign entities such as the biotech company Agenus, which is testing molecules in the United States. The first targets are colon and breast cancer, which together affect 16 thousand Brazilians every year.
A member of the Centro de Oncologia Dayan-Daycoval do Hospital Israelita Albert Einstein’s committee, and an integral part of the medical board at the ARD Foundation, Doctor Antonio C. Buzaid commented on Recepta Bipharma’s initiative with enthusiasm.
– Recepta is a Brazilian company that is developing checkpoint inhibitors, both antiCTLA-4 and antiPD-1, to treat cancer. Not only is their work of high quality, the company believes that they will be able to reduce costs by approximately 80%, giving SUS access to these medications. I have no doubts that this will be a reality in the near future and that Brazil will be proud of Recepta – says Dr. Buzaid, having created in 1998 along with Dr. Raul Cutait and Dr. Frederico Costa, the oncology center at the Hospital Sírio Libanes.